40
LeanBio Therapeutics files indefinite biotech raise under Reg D in Massachusetts
Company raise · Pre-first close · BROOKLINE, MA · Form D filed 2026-10-22
LeanBio Therapeutics, a Delaware corporation incorporated in 2026, filed a new Form D for an indefinite offering under Regulation D exemptions 4(a)(5) and Reg D(b). The company, based in Brookline, MA, has not yet made its first sale and lists zero investors to date.
Note: Company incorporated in 2026 (current year); first raise on EDGAR; no placement agent listed; indefinite offering amount; zero investors and sales to date as of filing.
First raise on EDGARoperating_company
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
People on the filing
| Michal Preminger | Executive Officer, Director |
| William Hait | Executive Officer, Director |
Signed by Brian W. Pusch, Secretary.
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.